Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease : an Official Journal of the Transplantation Society
B D AlexanderJohn Perfect

Abstract

Allogeneic hematopoietic stem cell transplant (HSCT) recipients are at increased risk for invasive fungal infections (IFIs) over prolonged periods of time. Aerosolized amphotericin B lipid complex (ABLC) has shown promise in lung transplant recipients as a convenient means of delivering protective drug to the upper airways avoiding systemic toxicities. The safety and tolerability of aerosolized ABLC in 40 subjects undergoing allogeneic HSCT was prospectively investigated in an open-labeled, non-comparative study. Subjects received aerosolized ABLC treatment once daily for 4 days, then once weekly for 13 weeks; fluconazole was administered daily as standard of care through post-transplant day 100. Pulmonary mechanics were measured before and after each dose of inhaled ABLC; adverse events (AEs) and the development of IFI were also monitored. Cough, nausea, taste disturbance, or vomiting followed 2.2% of 458 total inhaled ABLC administrations; 5.2% of inhaled ABLC administrations were associated with >or=20% decrease in pulmonary function measurements (forced expiratory volume in 1 second or forced vital capacity) and none required treatment with bronchodilators or withdrawal from study. Four mild AEs were considered possibly or ...Continue Reading

References

May 1, 1992·The Journal of Infectious Diseases·J R PerfectW P Peters
Nov 1, 1988·Antimicrobial Agents and Chemotherapy·H J SchmittD Armstrong
Dec 1, 1994·The American Journal of Medicine·D K RileyT G Evans
Jun 1, 1994·The American Journal of Medicine·V A MorrisonD J Weisdorf
May 1, 1997·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Z ErjavecM R Halie
Jun 14, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D P KontoyiannisK V Rolston
Dec 4, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S AsciogluUNKNOWN Mycoses Study Group of the National Institute of Allergy and Infectious Diseases
Mar 7, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kieren A MarrLawrence Corey
Oct 2, 2002·Journal of Clinical Microbiology·M A Pfaller, D J Diekema
Sep 25, 2003·Blood·Kieren A MarrGeorge B McDonald
Feb 27, 2004·The New England Journal of Medicine·Francisco M MartyLindsey R Baden
Sep 10, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Alexander ImhofKieren A Marr
Sep 10, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Greg T SiwekMichael A Pfaller
Nov 17, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jo-Anne H van BurikUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group

❮ Previous
Next ❯

Citations

Apr 2, 2008·Current Infectious Disease Reports·Shin-Woo KimDavid P Nicolau
May 16, 2009·Medical Mycology·Georg MaschmeyerJohn Perfect
Jan 8, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas J WalshUNKNOWN Infectious Diseases Society of America
May 20, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G MaschmeyerUNKNOWN Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology
Mar 18, 2009·Antimicrobial Agents and Chemotherapy·Justin A TolmanRobert O Williams
May 27, 2010·Current Fungal Infection Reports·Jennifer Le, Daryl S Schiller
Dec 8, 2010·Expert Review of Anti-infective Therapy·Nikolaos G Almyroudis, Brahm H Segal
Sep 20, 2007·Expert Opinion on Drug Safety·Stephanie A Knechtel, Michael E Klepser
Jan 1, 2010·Medicina clínica·Rafael de la CámaraMiguel Angel Sanz
May 17, 2008·Pediatric Transplantation·Nihar BhaktaRobert Ettenger
Jul 14, 2011·Transplant Infectious Disease : an Official Journal of the Transplantation Society·A NihtinenL Volin
Oct 3, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eyal RobenshtokMical Paul
May 27, 2009·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Laura Kuiper, Elisabeth J Ruijgrok
Jul 1, 2011·The Korean Journal of Internal Medicine·Dong-Gun LeeJung-Hyun Choi
Jun 1, 2008·Current Fungal Infection Reports·John W Baddley, Senu Apewokin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.